Author’s Reply to Peronard and Mayntz: “SGLT2 Inhibitors, and How They Work Beyond the Glucosuric Effect”
| datacite.rights | http://purl.org/coar/access_right/c_14cb | |
| dc.contributor.author | Aristizábal‑Colorado, David | |
| dc.contributor.author | Ocampo‑Posada, Martín | |
| dc.contributor.author | Rivera‑Martínez, Wilfredo Antonio | |
| dc.contributor.author | Corredor‑Rengifo, David | |
| dc.contributor.author | Rico‑Fontalvo, Jorge | |
| dc.contributor.author | Gómez‑Mesa, Juan Esteban | |
| dc.contributor.author | Duque‑Ossman, John Jairo | |
| dc.contributor.author | Abreu‑Lomba, Alin | |
| dc.date.accessioned | 2024-12-17T22:49:06Z | |
| dc.date.available | 2024-12-17T22:49:06Z | |
| dc.date.issued | 2024 | |
| dc.description.abstract | We would like to express our sincere gratitude to the reviewers for their thoughtful and detailed comments on our article. We hope that our responses adequately address their concerns and that this exchange of ideas contributes to a broader understanding of the topic. We believe that letters to the editor serve as valuable platforms for scholarly discussion and the dissemination of knowledge. We encourage continued dialogue and debate on this important subject. | eng |
| dc.format.mimetype | ||
| dc.identifier.citation | Aristizábal-Colorado, D., Ocampo-Posada, M., Rivera-Martínez, W.A. et al. Author’s Reply to Peronard and Mayntz: “SGLT2 Inhibitors, and How They Work Beyond the Glucosuric Effect”. Am J Cardiovasc Drugs (2024). https://doi.org/10.1007/s40256-024-00707-8 | eng |
| dc.identifier.doi | https://doi.org/10.1007/s40256-024-00707-8 | |
| dc.identifier.issn | 11753277 (Impreso) | |
| dc.identifier.issn | 1179187X (Electrónico) | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12442/16077 | |
| dc.identifier.url | https://link.springer.com/article/10.1007/s40256-024-00707-8 | |
| dc.language.iso | eng | |
| dc.publisher | Springer Nature | eng |
| dc.rights | Attribution-NonCommercial-NoDerivs 3.0 United States | eng |
| dc.rights.accessrights | info:eu-repo/semantics/closedAccess | |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/3.0/us/ | |
| dc.title | Author’s Reply to Peronard and Mayntz: “SGLT2 Inhibitors, and How They Work Beyond the Glucosuric Effect” | eng |
| dc.type.driver | info:eu-repo/semantics/article | |
| dc.type.spa | Artículo científico | |
| dcterms.references | Peronard R, Mayntz S. Comment on “SGLT2 inhibitors, and how they work beyond the glucosuric effect”. Am J Cardiovasc Drugs 2024. https:// doi. org/ 10. 1007/ s40256- 024- 00706-9. | eng |
| dcterms.references | Aristizabal-Colorado D, Corredor-Renfigo D, Vernaza Trujillo D, Galvis C, Abreu-Lomba A. Semaglutide versus empagliflozine, a cohort study with 18 months follow-up (SEMPA18). EV362/#968 E-poster topic: AS10. New medications for treatment of diabetes. Diabetes Technol Ther. 2024;26:A-289. https:// doi. org/ 10. 1089/ dia. 2024. 2525. abstr acts. | eng |
| dcterms.references | Corredor-Rengifo D, Vernaza Trujillo D, Galvis C, Aristizabal- Colorado D, Abreu A. Effect of ISGLT2 on hospitalizations for heart failure and metabolic control in diabetic adults over 60 years of age. EV360/#942 e-poster topic: AS10 new medications for treatment of diabetes. Diabetes Technol Ther. 2024;26:A-288. https:// doi. org/ 10. 1089/ dia. 2024. 2525. abstr acts. | eng |
| dcterms.references | Medina Amaya NG, Moreno Cabrera JD. Análisis de costoutilidad de los inhibidores del SGLT2 (Empagliflozina, Dapagliflozina) para el tratamiento de pacientes con falla cardiaca con fracción de eyección reducida (HFrEF) y NYHA II-IV en Colombia [Cost-utility analysis of SGLT2 inhibitors (Empagliflozin, Dapagliflozin) for the treatment of patients with heart failure with reduced ejection fraction (HFrEF) and NYHA II-IV in Colombia]; 2022. | spa |
| dcterms.references | Neal B, Perkovic V, Matthews DR. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:2099. https:// doi. org/ 10. 1056/ NEJMc 17125 72. | eng |
| dcterms.references | Cowan A, Jeyakumar N, Kang Y, Dixon SN, Garg AX, Naylor K, et al. Fracture risk of sodium-glucose cotransporter-2 inhibitors in chronic kidney disease. Clin J Am Soc Nephrol CJASN. 2022;17:835–42. https:// doi. org/ 10. 2215/ CJN. 16171 221. | eng |
| dcterms.references | Bhanushali KB, Asnani HK, Nair A, Ganatra S, Dani SS. Pharmacovigilance study for SGLT 2 inhibitors—safety review of real-world data & randomized clinical trials. Curr Problem Cardiol. 2024;49: 102664. https:// doi. org/ 10. 1016/j. cpcar diol. 2024. 102664. | eng |
| dcterms.references | Obrador GT, Álvarez-Estévez G, Bellorin-Font E, Bonanno- Hidalgo C, Clavero R, Correa-Rotter R, et al. Documento de consenso sobre nuevas terapias para retrasar la progresión de la enfermedad renal crónica con énfasis en los iSGLT-2: implicaciones para Latinoamérica. Rev Nefrol Latinoam. 2024;21:1–18. https:// doi. org/ 10. 24875/ NEFRO. M2400 0037. | spa |
| dcterms.references | See RM, Teo YN, Teo YH, Syn NL, Yip ASY, Leong S, et al. Effects of sodium-glucose cotransporter 2 on amputation events: a systematic review and meta-analysis of randomized-controlled trials. Pharmacology. 2022;107:123–30. https:// doi. org/ 10. 1159/ 00052 0903. | eng |
| dcterms.references | Dong B, Lv R, Wang J, Che L, Wang Z, Huai Z, et al. The extraglycemic effect of SGLT-2is on mineral and bone metabolism and bone fracture. Front Endocrinol. 2022. https:// doi. org/ 10. 3389/ fendo. 2022. 918350. | eng |
| dcterms.references | American Diabetes Association Professional Practice Committee. 9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2024. Diabetes Care. 2024;47:S158–78. https:// doi. org/ 10. 2337/ dc24- S009. | eng |
| dcterms.references | Sukhera J. Narrative reviews: flexible, rigorous, and practical. J Grad Med Educ. 2022;14:414–7. https:// doi. org/ 10. 4300/ JGME-D- 22- 00480.1. | eng |
| dcterms.references | Aristizábal-Colorado D, Ocampo-Posada M, Rivera-Martínez WA, Corredor-Rengifo D, Rico-Fontalvo J, Gómez-Mesa JE, et al. SGLT2 inhibitors and how they work beyond the glucosuric effect. State of the Art. Am J Cardiovasc Drugs. 2024. https:// doi. org/ 10. 1007/ s40256- 024- 00673-1. | eng |
| oaire.version | info:eu-repo/semantics/publishedVersion |
Archivos
Bloque de licencias
1 - 1 de 1
No hay miniatura disponible
- Nombre:
- license.txt
- Tamaño:
- 381 B
- Formato:
- Item-specific license agreed upon to submission
- Descripción: